These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 29871823

  • 1. Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.
    Steinmetz MO, Prota AE.
    Trends Cell Biol; 2018 Oct; 28(10):776-792. PubMed ID: 29871823
    [Abstract] [Full Text] [Related]

  • 2. Natural products as antimitotic agents.
    Dall'Acqua S.
    Curr Top Med Chem; 2014 Oct; 14(20):2272-85. PubMed ID: 25434355
    [Abstract] [Full Text] [Related]

  • 3. [Antimitotic agents].
    Fukuoka K, Saijo N.
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1519-25. PubMed ID: 9309150
    [Abstract] [Full Text] [Related]

  • 4. A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel.
    França F, Silva PMA, Soares JX, Henriques AC, Loureiro DRP, Azevedo CMG, Afonso CMM, Bousbaa H.
    Molecules; 2020 Dec 10; 25(24):. PubMed ID: 33322077
    [Abstract] [Full Text] [Related]

  • 5. Zerumbone, a cyclic sesquiterpene, exerts antimitotic activity in HeLa cells through tubulin binding and exhibits synergistic activity with vinblastine and paclitaxel.
    Ashraf SM, Sebastian J, Rathinasamy K.
    Cell Prolif; 2019 Mar 10; 52(2):e12558. PubMed ID: 30525278
    [Abstract] [Full Text] [Related]

  • 6. Recent progress in discovery and development of antimitotic agents.
    Kiselyov A, Balakin KV, Tkachenko SE, Savchuk N, Ivachtchenko AV.
    Anticancer Agents Med Chem; 2007 Mar 10; 7(2):189-208. PubMed ID: 17348827
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.
    Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M.
    FEBS J; 2006 Jul 10; 273(14):3301-10. PubMed ID: 16803461
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids.
    Coderch C, Morreale A, Gago F.
    Anticancer Agents Med Chem; 2012 Mar 10; 12(3):219-25. PubMed ID: 22044006
    [Abstract] [Full Text] [Related]

  • 11. Mitosis is not a key target of microtubule agents in patient tumors.
    Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T.
    Nat Rev Clin Oncol; 2011 Feb 01; 8(4):244-50. PubMed ID: 21283127
    [Abstract] [Full Text] [Related]

  • 12. Microtubule-Targeting Drugs: More than Antimitotics.
    Kaul R, Risinger AL, Mooberry SL.
    J Nat Prod; 2019 Mar 22; 82(3):680-685. PubMed ID: 30835122
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Target driven preclinical screening for new antimitotic chemotherapy agents.
    Novío S, Freire-Garabal M, Núñez MJ.
    Curr Top Med Chem; 2014 Mar 22; 14(20):2263-71. PubMed ID: 25434356
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA.
    Curr Med Chem Anticancer Agents; 2002 Jan 22; 2(1):1-17. PubMed ID: 12678749
    [Abstract] [Full Text] [Related]

  • 20. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y, Yin S, Blade K, Cooper G, Menick DR, Cabral F.
    Biochemistry; 2006 Jan 10; 45(1):185-94. PubMed ID: 16388594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.